Protalix BioTherapeutics (PLX) Other Accumulated Expenses (2023 - 2026)

Protalix BioTherapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $973000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 224.33% year-over-year to $973000.0 in Q1 2026; TTM through Mar 2026 was $973000.0, a 224.33% increase from a year earlier, with the FY2025 full-year figure at $799000.0, down 26.02% from the prior year.
• Other Accumulated Expenses advanced to $973000.0 in Q1 2026 per PLX's latest filing, from $799000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.1 million in Q4 2024 and bottomed at $300000.0 in Q1 2025.
• The 4-year median for Other Accumulated Expenses is $763000.0 (2025), against an average of $730000.0.
• Across the five-year window, Other Accumulated Expenses declined 26.02% in 2025 and surged 224.33% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $637000.0 in 2023, then jumped by 69.54% to $1.1 million in 2024, then retreated by 26.02% to $799000.0 in 2025, then grew by 21.78% to $973000.0 in 2026.
• Per Business Quant, the three latest PLX Other Accumulated Expenses figures stand at $973000.0 (Q1 2026), $799000.0 (Q4 2025), and $558000.0 (Q3 2025).